Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 144 participants.
Also called NCT06712615
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 144 participants
- Sponsor
- ProGen. Co., Ltd.
- Registry
-
NCT06712615
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06712615. Randomized; double masking; primary purpose treatment. Start 2024-12-05 (actual); primary completion 2025-10-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Condition
- Obesity Type 2 Diabetes Mellitus
- Intervention (Biological)
- PG-102
- Intervention (Other)
- Placebo
- Lead sponsor
- ProGen. Co., Ltd.
Record details
- Record id
cardio:ct-nct06712615- Content hash
b6ebb3568ffa85f79e47daa49c5662486d3bcd9da7d979d80ed88b76b96e2e80